๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Cost-utility analysis of imatinib mesylate for the treatment ofchronic myelogenous leukemia in the chronic phase

โœ Scribed by Emma Warren; Sue Ward; Adam Gordois; Paul Scuffham

Book ID
116371689
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
783 KB
Volume
26
Category
Article
ISSN
0149-2918

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

The significance of myelosuppression dur
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
โœ Thomas B. Sneed; Hagop M. Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rio ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 82 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression โ‰ฅ Grade 3, requiring interruption of thera